Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


24.10.2022

1 Am J Surg
1 Am J Surg Pathol
4 Ann Surg Oncol
7 BMC Cancer
2 Breast Cancer
3 Breast Cancer (Dove Med Press)
2 Breast Cancer Res
4 Breast Cancer Res Treat
1 Breast J
2 Cancer
2 Cancer Chemother Pharmacol
2 Cancer Res
2 Clin Cancer Res
1 Eur J Cancer
2 Gene
1 Int J Oncol
1 Int J Radiat Oncol Biol Phys
1 J Biol Chem
1 J Clin Oncol
1 Nat Rev Clin Oncol
4 Oncogene
2 PLoS One
3 Proc Natl Acad Sci U S A
1 Radiol Imaging Cancer
4 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Surg

  1. CHENG D, Baynosa J, Cross C, Kirgan D, et al
    Comparing the effect of distance to treatment facility on reconstruction and breast conservation therapy for early-stage invasive ductal carcinoma between the nation and the mountain region.
    Am J Surg. 2022;224:1049-1056.
    PubMed         Abstract available


    Am J Surg Pathol

  2. PEREZ-MIES B, Caniego-Casas T, Carretero-Barrio I, Biscuola M, et al
    The Clonal Relationship Between the Ductal and Lobular Components of Mixed Ductal-Lobular Carcinomas Suggested a Ductal Origin in Most Tumors.
    Am J Surg Pathol. 2022;46:1545-1553.
    PubMed         Abstract available


    Ann Surg Oncol

  3. KO G, Hallet J, Jerzak KJ, Chan W, et al
    Low Rates of Medical Oncology Consultation for Older Women (>/= 70 Years) with Newly Diagnosed, Non-Metastatic Breast Cancer: A Population-Based Study.
    Ann Surg Oncol. 2022 Oct 18. pii: 10.1245/s10434-022-12640.
    PubMed         Abstract available

  4. KHAN SY, Melkus MW, Layeequr Rahman R
    ASO Author Reflections: Cryoablation Cost-Benefit Analysis: Managing Breast Cancer Through Cost-Effective Therapy.
    Ann Surg Oncol. 2022 Oct 16. pii: 10.1245/s10434-022-12669.
    PubMed        

  5. SCHWARTZ T, Marumoto AD, Giuliano AE
    ASO Author Reflections: The Evolution of Axillary Management in Breast Cancer.
    Ann Surg Oncol. 2022 Oct 16. pii: 10.1245/s10434-022-12677.
    PubMed        

  6. CULVER JO
    ASO Author Reflections: A Green Light for Genetic Testing in All Patients with Breast Cancer.
    Ann Surg Oncol. 2022 Oct 14. pii: 10.1245/s10434-022-12671.
    PubMed        


    BMC Cancer

  7. LIU L, Zhai W, Wang F, Yu L, et al
    Using machine learning to identify gene interaction networks associated with breast cancer.
    BMC Cancer. 2022;22:1070.
    PubMed         Abstract available

  8. ISMAIL AL-KHALIL W, Al-Salhi L, Rijjal S, Aljamali M, et al
    The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.
    BMC Cancer. 2022;22:1067.
    PubMed         Abstract available

  9. KORONKIEWICZ M, Kazimierczuk Z, Orzeszko A
    Antitumor activity of the protein kinase inhibitor 1-(beta-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines.
    BMC Cancer. 2022;22:1069.
    PubMed         Abstract available

  10. YAN D, Ju X, Luo B, Guan F, et al
    Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer.
    BMC Cancer. 2022;22:1082.
    PubMed         Abstract available

  11. CHERIFI F, Da Silva A, Johnson A, Blanc-Fournier C, et al
    HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
    BMC Cancer. 2022;22:1081.
    PubMed         Abstract available

  12. NABI-MEYBODI M, Sahebnasagh A, Hakimi Z, Shabani M, et al
    Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial.
    BMC Cancer. 2022;22:1079.
    PubMed         Abstract available

  13. HAYNES BM, Cunningham K, Shekhar MPV
    RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    BMC Cancer. 2022;22:1073.
    PubMed         Abstract available


    Breast Cancer

  14. SUZUKI K, Sasada S, Nishi H, Kimura Y, et al
    Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.
    Breast Cancer. 2022 Oct 21. pii: 10.1007/s12282-022-01410.
    PubMed         Abstract available

  15. SEKIGUCHI K, Sumi M, Saito A, Zenda S, et al
    The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 Oct 18. pii: 10.1007/s12282-022-01403.
    PubMed         Abstract available


    Breast Cancer (Dove Med Press)

  16. DAVEY MG, Kerin MJ
    Evaluating the Fragility of Long-Term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy Prescription in Early Breast Cancer: Pooled Data from 10 Randomised Clinical Trials.
    Breast Cancer (Dove Med Press). 2022;14:343-350.
    PubMed         Abstract available

  17. WANG S, Wei Y, Li Z, Xu J, et al
    Development and Validation of an MRI Radiomics-Based Signature to Predict Histological Grade in Patients with Invasive Breast Cancer.
    Breast Cancer (Dove Med Press). 2022;14:335-342.
    PubMed         Abstract available

  18. CAPUTO R, Fabi A, Romagnoli E, Baldini E, et al
    Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial.
    Breast Cancer (Dove Med Press). 2022;14:351-362.
    PubMed         Abstract available


    Breast Cancer Res

  19. ZHENG ZY, Elsarraj H, Lei JT, Hong Y, et al
    Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
    Breast Cancer Res. 2022;24:68.
    PubMed         Abstract available

  20. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:69.
    PubMed         Abstract available


    Breast Cancer Res Treat

  21. LAITMAN Y, Nielsen SM, Bernstein-Molho R, Heald B, et al
    Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis.
    Breast Cancer Res Treat. 2022;196:355-361.
    PubMed         Abstract available

  22. NICOSIA L, Lissidini G, Sargenti M, Bozzini AC, et al
    Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center.
    Breast Cancer Res Treat. 2022;196:371-377.
    PubMed         Abstract available

  23. VIHERVUORI H, Korpinen K, Autere TA, Repo H, et al
    Varying outcomes of triple-negative breast cancer in different age groups-prognostic value of clinical features and proliferation.
    Breast Cancer Res Treat. 2022 Oct 19. pii: 10.1007/s10549-022-06767.
    PubMed         Abstract available

  24. TOOHEY K, Hunter M, McKinnon K, Casey T, et al
    systematic review of multimodal prehabilitation in breast cancer.
    Breast Cancer Res Treat. 2022 Oct 21. pii: 10.1007/s10549-022-06759.
    PubMed         Abstract available


    Breast J

  25. TASLI F, Cavdar D, Kececi SD, Zengel B, et al
    The Importance of the Pathological Perspective in the Management of the Invasive Lobular Carcinoma.
    Breast J. 2022;2022:2461242.
    PubMed         Abstract available


    Cancer

  26. GENNARO M, Maccauro M, Mariani L, Listorti C, et al
    Occurrence of breast-cancer-related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial.
    Cancer. 2022 Oct 19. doi: 10.1002/cncr.34498.
    PubMed         Abstract available

  27. DURHAM DD, Abraham LA, Roberts MC, Khan CP, et al
    Breast cancer incidence among women with a family history of breast cancer by relative's age at diagnosis.
    Cancer. 2022 Oct 19. doi: 10.1002/cncr.34365.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  28. JIAN W, Xue J, Yao Q, Chen R, et al
    Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic-pharmacodynamic model of neutropenia.
    Cancer Chemother Pharmacol. 2022 Oct 22. pii: 10.1007/s00280-022-04484.
    PubMed         Abstract available

  29. SHARAF BM, Giddey AD, Al-Hroub HM, Menon V, et al
    Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab.
    Cancer Chemother Pharmacol. 2022 Oct 20. pii: 10.1007/s00280-022-04478.
    PubMed         Abstract available


    Cancer Res

  30. TARANTINO P, Tolaney SM
    The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.
    Cancer Res. 2022;82:3659-3661.
    PubMed         Abstract available

  31. BLAWSKI R, Toska E
    A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
    Cancer Res. 2022;82:3668-3670.
    PubMed         Abstract available


    Clin Cancer Res

  32. GAZINSKA P, Milton C, Iacovacci J, Ward J, et al
    Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
    Clin Cancer Res. 2022;28:4494-4508.
    PubMed         Abstract available

  33. ELIA A, Saldain L, Vanzulli SI, Helguero LA, et al
    Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial.
    Clin Cancer Res. 2022 Oct 21. pii: 709943. doi: 10.1158/1078-0432.CCR-22-2060.
    PubMed         Abstract available


    Eur J Cancer

  34. KREGTING LM, Olthof EMG, Breekveldt ECH, Aitken CA, et al
    Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
    Eur J Cancer. 2022;175:180-186.
    PubMed         Abstract available


    Gene

  35. TARAN Z, Yektaniroumand Digehsaraei S, Salouti M, Amini B, et al
    Methotrexate loaded in alginate beads for controlled drug release against breast cancer.
    Gene. 2022;851:146941.
    PubMed         Abstract available

  36. SGHAIER I, Zidi S, El-Ghali RM, Daldoul A, et al
    Unique ESR1 and ESR2 estrogen receptor gene variants associated with altered risk of triple-negative breast cancer: a case-control study.
    Gene. 2022 Oct 16:146969. doi: 10.1016/j.gene.2022.146969.
    PubMed         Abstract available


    Int J Oncol

  37. MENG Z, Zhang R, Wu X, Zhang M, et al
    PDL1 mediates triplenegative breast cancer evolution via the regulation of TAM/M2 polarization.
    Int J Oncol. 2022;61.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  38. GOODMAN CR, Strauss JB
    One Way or Another: An Oligorecurrence After an Oligometastasis of an Estrogen Receptor-Positive Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2022;114:571-572.
    PubMed        


    J Biol Chem

  39. GUO Q, Qiu Y, Liu Y, He Y, et al
    Cell adhesion molecule CD44v10 promotes stem-like properties in triple-negative breast cancer cells via glucose transporter GLUT1-mediated glycolysis.
    J Biol Chem. 2022 Oct 12:102588. doi: 10.1016/j.jbc.2022.102588.
    PubMed         Abstract available


    J Clin Oncol

  40. WONG FL, Lee JM, Leisenring WM, Neglia JP, et al
    Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2022 Oct 20:JCO2200574. doi: 10.1200/JCO.22.00574.
    PubMed         Abstract available


    Nat Rev Clin Oncol

  41. AGOSTINETTO E, Gligorov J, Piccart M
    Systemic therapy for early-stage breast cancer: learning from the past to build the future.
    Nat Rev Clin Oncol. 2022 Oct 17. pii: 10.1038/s41571-022-00687.
    PubMed         Abstract available


    Oncogene

  42. DUNN S, Eberlein C, Yu J, Gris-Oliver A, et al
    AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
    Oncogene. 2022 Oct 14. pii: 10.1038/s41388-022-02482.
    PubMed         Abstract available

  43. YOUSEFI H, Khosla M, Lauterboeck L, Okpechi SC, et al
    A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.
    Oncogene. 2022 Oct 15. pii: 10.1038/s41388-022-02497.
    PubMed         Abstract available

  44. TWAFRA S, Sokolik CG, Sneh T, Srikanth KD, et al
    A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis.
    Oncogene. 2022 Oct 18. pii: 10.1038/s41388-022-02481.
    PubMed         Abstract available

  45. UNLU B, Kocaturk B, Rondon AMR, Lewis CS, et al
    Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer.
    Oncogene. 2022 Oct 21. pii: 10.1038/s41388-022-02511.
    PubMed         Abstract available


    PLoS One

  46. A MOHAMED E, Gaber T, Karam O, Rashed EA, et al
    A Novel CNN pooling layer for breast cancer segmentation and classification from thermograms.
    PLoS One. 2022;17:e0276523.
    PubMed         Abstract available

  47. CHAN WY, Cheah WK, Ramli Hamid MT, Md Shah MN, et al
    Impact of preoperative magnetic resonance imaging on surgery and eligibility for intraoperative radiotherapy in early breast cancer.
    PLoS One. 2022;17:e0274385.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  48. GARAN LAW, Xiao Y, Lin WC
    14-3-3tau drives estrogen receptor loss via ERalpha36 induction and GATA3 inhibition in breast cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2209211119.
    PubMed         Abstract available

  49. MICALIZZI DS, Che D, Nicholson BT, Edd JF, et al
    Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody.
    Proc Natl Acad Sci U S A. 2022;119:e2209563119.
    PubMed         Abstract available

  50. TU Z, Hu Y, Raizada D, Bassal MA, et al
    Long noncoding RNA-mediated activation of PROTOR1/PRR5-AKT signaling shunt downstream of PI3K in triple-negative breast cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2203180119.
    PubMed         Abstract available


    Radiol Imaging Cancer

  51. MAKHLIN I, Korhonen KE, Martin ML, Gillman J, et al
    (18)F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer.
    Radiol Imaging Cancer. 2022;4:e220032.
    PubMed         Abstract available


    Radiother Oncol

  52. THOMSEN MS, Alsner J, Nielsen HM, Jakobsen EH, et al
    Volume matters: Breast induration is associated with irradiated breast volume in the Danish Breast Cancer Group phase III randomized Partial Breast Irradiation trial.
    Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04494.
    PubMed         Abstract available

  53. LAZZARI G, Rago L, Solazzo AP, Benevento I, et al
    Adjuvant chemotherapy and hypofractionated whole breast cancer radiotherapy: is it time to rethink the sequencing ?
    Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04507.
    PubMed        

  54. VROU OFFERSEN B, Overgaard M, Overgaard J
    Breast cancer radiotherapy: is it time to rethink the indication?
    Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04505.
    PubMed        

  55. TUDDA A, Castriconi R, Benecchi G, Cagni E, et al
    Knowledge-based multi-institution plan prediction of whole breast irradiation with tangential fields.
    Radiother Oncol. 2022;175:10-16.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: